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Abstract
Background When a liver lesion diagnosed as focal nodular hyperplasia (FNH) increases in size, it may cause doubt
about the initial diagnosis. In many cases, additional investigations will follow to exclude hepatocellular adenoma or
malignancy. This retrospective cohort study addresses the implications of growth of FNH for clinical management.
Methods We included patients diagnosed with FNH based on C2 imaging modalities between 2002 and 2015.
Characteristics of patients with growing FNH with sequential imaging in a 6-month interval were compared to non-
growing FNH.
Results Growth was reported in 19/162 (12%) patients, ranging from 21 to 200%. Resection was performed in 4/19
growing FNHs; histological examination confirmed FNH in all patients. In all 15 conservatively treated patients,
additional imaging confirmed FNH diagnosis. No adverse outcomes were reported. No differences were found in
characteristics and presentation of patients with growing or non-growing FNH.
Conclusion This study confirms that FNH may grow significantly without causing symptoms. A significant increase
in size should not have any implications on clinical management if confident diagnosis by imaging has been
established by a tertiary benign liver multidisciplinary team. Liver biopsy is only indicated in case of doubt after
state-of-the-art imaging. Resection is deemed unnecessary if the diagnosis is confirmed by multiple imaging
modalities in a tertiary referral centre.
Introduction
Focal nodular hyperplasia (FNH) is a benign liver tumour
with an incidence in the general population of 0.6–3% [1].
FNH is especially common in young women, with a male/
female ratio of 1:12 [2]. So far, no explanation has been
found for the gender bias; female hormones or the use of
oral contraceptives do not seem to play a role in prevalence
[3, 4].
An FNH lesion consists of benign hepatocytes sur-
rounding a central fibrous scar with a prominent dystrophic
artery. The underlying mechanism of FNH formation is
thought to be due to a vascular malformation and injury
[5]. Patients do not have an underlying liver disease and are
mostly asymptomatic [6].
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With the current availability of highly sensitive imaging
techniques, FNH is diagnosed more often as an incidental
lesion. Magnetic resonance imaging (MRI) with liver-
specific contrast agents has a very high specificity of
almost 100% in larger lesions ([3 cm) but is less accurate
with a sensitivity of 70–80% to diagnose smaller lesions
where the central scar may be missing. In these cases, the
combination of MRI and contrast-enhanced ultrasound
(CEUS) provides the highest diagnostic accuracy [7].
This year, the European Association for the Study of the
Liver (EASL) issued the first clinical practice guideline for
benign liver tumours [8] in which they state that treatment
of FNH is not recommended because of the benign char-
acter of FNH, the low incidence of intralesional bleeding
[9, 10] and the absence of malignant transformation [11].
In case of doubt about the diagnosis FNH, a biopsy may be
considered [8]. The guideline describes treatment is only
pursued in exceptional cases such as expanding FNH.
It has been documented that FNH lesions may show a
slow and incidental increase in size during follow-up.
However, change in size may cause doubt about the
diagnosis and the benign character of the liver lesion [12].
Growth of FNH has been suggested to be an indication for
resection [13–15], although evidence for this approach is
weak. The aim of this study was to evaluate how often a
FNH grows and what are the implications for management
and compare the characteristics of those with and without
growing FNH.
Materials and methods
To evaluate the course of disease of FNH lesions increas-
ing in size during follow-up, we performed a retrospective
cohort study including all patients who had been diagnosed
with FNH in the Erasmus University Medical Centre, a
tertiary referral centre for focal liver lesions. Inclusion
started in 2002, from the moment that we had the avail-
ability of two imaging techniques with high sensitivity and
specificity to establish the diagnosis FNH, and ran until
2015. Diagnosis FNH had to be confirmed on at least two
radiologic modalities, including at least one contrast-en-
hanced MRI and one contrast-enhanced CT scan or CEUS,
and established in a multidisciplinary tumour board com-
mittee. Sequential imaging had to be available with at least
a 6-month interval.
Baseline characteristics, including gender, age and body
mass index (BMI), were collected from electronic patient
records. Patients were scored as symptomatic if abdominal
pain or general discomfort was reported in history. Infor-
mation on the number and size of the FNH lesions was
collected from radiological and histological reports. Data
on clinical management were obtained from the reports of
the multidisciplinary tumour board committee and corre-
lated with data obtained from surgical, radiological and
pathological reports.
The radiological reports of all patients were re-exam-
ined, and growth was established if an increase in size
between the diagnostic scan (T1) and follow-up scan at
least 6 months after the initial scan (T2) was found. The
diagnostic and follow-up scans were reassessed indepen-
dently by two experienced radiologists (R.D. and I.P) from
two tertiary referral centres. Because of the imprecise
measurements of size in small lesions and potential bias in
outcome, patients with lesions\ 20 mm in both diagnostic
and follow-up scans were excluded. We defined growth as
an increase in size of at least 20% according to the RECIST
criteria for solid liver tumours [16], as no other criteria
have been validated. To evaluate whether lesion growth
was related to weight gain, additional thickness of the
subcutaneous fatty layer in the abdominal wall was mea-
sured on initial and follow-up imaging. Measurements
were performed by both radiologists separately in the
midline (linea alba) on the level of the origin of the coeliac
artery.
Radiology
In patients with a diagnosis of FNH who were found to
have an increase in size, the diagnostic and follow-up scans
were reviewed. MR imaging was performed with 1.5-T MR
systems using a standard MRI protocol of T1-weighted,
T2-weighted sequences and a dynamic contrast-enhanced
series after intravenous administration of a bolus of 30 ml
of non-liver-specific gadolinium chelate (gadopentetate
dimeglumine, Magnevist; Schering, Berlin, Germany). CT
scans were performed with 16- and 64-detector machines
with a multiphase CT protocol consisting of plain, arterial-
and portal-venous-dominant phase scans of the liver after
i.v administration of 120 cc (Visipaque, General Electric
Healthcare Medical Systems, Milwaukee, Wisconsin,
USA). The lesions were scored as typical FNH if they were
lobulated, a central scar was present, the aspect of the
lesion was homogenous on the diagnostic MRI conform
generally accepted classical imaging features of FNH. If
there was no consensus on diagnosis or MR imaging
showed no typical FNH, pathological examination had to
have been performed for patients to be included in this
study. Size measurements were done after complete eval-
uation of the MRI with confident diagnosis of FNH
assessed by the readers. After evaluation of all sequences,
measurements of lesion size were performed on images
that deemed most accurate for this purpose in the percep-
tion of the reader; both MRIs were measured in the same
phase. In most cases, this was done on the T1W after i.v
contrast infusion during the arterial-dominant phase. If
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imaging had been performed in collaborating hospitals
according to our protocol, the outcome would have been
reviewed in our hospital.
Data analysis
All analyses were performed using the Statistical Package
for the Social Sciences (SPSS) version 20.0 (SPSS, Chi-
cago, IL, USA). Continuous variables were summarized as
median and interquartile range and categorical data as
n (%) in case of a denominator[50 or a proportion/n in
case of denominator \50. Differences between groups
were assessed using the Mann–Whitney U test for contin-
uous variables and Chi-squared test for binary variables.
Correlation between variables was analysed using Pearson
product-moment correlation coefficient. Statistical signifi-
cance was considered at a p value\ 0.05.
Results and discussion
Out of 372 patients with a suspected FNH, 162 (44%) were
included for growth analysis as sequential imaging was
available with at least a 6-month interval (Fig. 1) and the
remaining 210 patients were excluded. Because follow-up
was less than 6 months, they were discharged when diag-
nosis FNH was established. Three patients were excluded
from growth analysis because the maximum diameter of
the lesion was\20 mm on both diagnostic and the follow-
up scan. The diagnosis FNH was confirmed by the two
radiologists in all cases. In 160 patients, the diameter
measurements from the first (T1) and last (T2) radiological
reports were examined, and in 28 patients (18%), an
increase in size was found. Confirmation of increase with at
least 20% was obtained in 19/28 patients as defined by both
radiologists (Fig. 2).
Patients with growing and non-growing FNH did not
differ regarding gender, age, BMI, number of lesions,
symptoms or use of oral contraceptives (Table 1). The
number of patients who underwent surgery or embolization
of FNH, and underwent follow-up for at least 6 months,
was significantly higher in the growing FNH group com-
pared to the non-growing FNH group (11 and 5%,
respectively, p = .009) although these patients had no
complaints. No adverse events occurred in the patients with
an FNH, including patients with growing FNH who did not
undergo treatment.
Diagnostic biopsy was performed in 18/162 patients
(11.1%): four histological examinations were inconclusive,
and 14 confirmed the diagnosis FNH. Indications for
biopsy were growth in four and uncertainty about the
diagnosis on imaging in 14.
In total, 11/162 (6.7%) patients underwent resection
(n = 9) or embolization (n = 2) of FNH. In all resected
cases, the diagnosis FNH was confirmed by histological
examination of the specimen. In 4/9, the radiological
diagnosis was uncertain, and in the remaining 5/9 patients,
the reason for resection was abdominal pain or dyspepsia.
Abdominal pain only resolved in one patient who under-
went treatment because of symptoms thought to be caused
by FNH, in the remaining four patients the surgery did not
provide symptom relief. The indication for embolization
was abdominal pain in both patients; neither of them
experienced symptom relief.
Growing FNHs
Characteristics of growing FNH are summarized in
Tables 2 and 3. In the growing FNH group, the median
follow-up time was 31 months (IQR 25–42). Growth per-
centage ranged from 21.1 to 200% (Fig. 3). The majority of
lesions (10/19) were located in the right hemiliver, and
9/12 were left-sided. Four patients underwent resection:
three is because growth caused doubt about the diagnosis
and one because of a symptomatic lesion. Three resected
FNHs were located in the right lateral liver, and one in the
left lateral liver. Pathology reports of the resected lesions
all confirmed benign FNH. None of the patients who
underwent resection had a diagnostic biopsy of the lesion
before surgery.
In all 15 patients treated with a wait-and-see policy,
additional imaging was performed (MRI with liver-specific
contrast or CEUS) which confirmed the lesions to be FNH.
Thirteen out of these 15 were discharged from follow-up or
were referred back to their initial hospital; two patients
were kept in follow-up every 2–3 years according to their
own wishes.
There was no statistically significant correlation
between the growth percentage of the FNH and the per-
centage difference in subcutaneous fat (r = - .214,
p = .340).
Discussion
This study reports on a large series of patients with FNH
and their follow-up. A specific focus of attention in our
study was to evaluate if growth of FNH should have
implications on clinical management, as growth may cause
doubt about the initial diagnosis. In our study population,
12% of the lesions showed growth over a period of at least
6 months. It should be noted that this figure most probably
overestimates the incidence of growing FNH and there may
be a bias in observation as the patients included in our
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analysis were referred to a tertiary referral centre because
of uncertainty about the diagnosis and management.
The diagnosis FNH was confirmed by resection in four
patients and additional imaging in the form of MRI with
liver-specific contrast agents or CEUS in the rest of the
patients. No adverse events were reported in the group of
growing FNHs. In line with the studies of Weimann et al.
[15] who observed five patients with growing FNH and
Perrakis et al. [14] who described 13 patients with growing
FNH, we were unable to identify risk factors for growth.
In the 18 biopsies that were performed in our cohort, 14
(77.8%) confirmed FNH, while in a recent study from
Sannier et al. a diagnostic accuracy of 95% in 19 patients
was reported [17]. This could be explained by the fact that
the accuracy for histologically diagnosing FNH and espe-
cially the distinction from other solid liver tumours such as
hepatocellular adenoma and hepatocellular carcinoma has
Fig. 1 Flow chart inclusion
Fig. 2 Example of a growing FNH. a FNH at T1: diameter 29 mm.
b FNH at T2: diameter 55 mm
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improved significantly in the study period. In 2009, Biou-
lac-Sage et al. [18] published a paper in which they were
the first to describe abundant expression of glutamine
synthetase as a marker to distinguish FNH from other
hepatic lesions.
Our results suggest that growth of FNH is quite common
and that growth in itself should not have any implications
Table 1 Patient and lesion characteristics
Growing FNH (n = 19) Non-growing FNH (n = 143) p value
Female 19/19 137 (96%) .363
Age 33 (24–42) 34 (27–43) .248
BMI 25.5 (24–29) 24.7 (22–30) .351
Lesions .677
Solitary 12/19 76 (53%)
Multiple 7/19 67 (47%)
Symptoms .962
None 5/19 38 (27%)
Upper abdominal pain 10/19 73 (51%)
Atypical complaints 3/19 18 (13%)
Elevated liver enzymes 1/19 10 (7%)
Unknown 0/19 3 (2%)
Treatment .009
No 15/19 136 (95%)
Yes 4/19 7 (5%)
Table 2 Lesion characteristics of growing FNH
Patient Time between imaging
sessions (weeks)
Number
of lesions
Maximum diameter first
imaging session (mm)
Maximum diameter last
imaging session (mm)
Percentage
increase T1–T2
(%)
Increase
subcutis mm
(%)
1 136,148 7 34*26 44*37 29.4 20.50 (141%)
2 137 3 76*58 92*64 21.1 2.50 (14%)
3 149 1 35*25 57*47 62.9 - 1.00 (- 13%)
4 319 1 61*57 86*74 41.0 - 4.50 (- 13%)
5 185 1 8*7 24*23 200.0 .50 (2%)
6 118 1 77*71 97*87 26.0 - .50 (- 2%)
7 258 5 66*48 83*53 25.8 3.00 (9%)
8 235 1 54*46 76*65 40.7 - 1.00 (- 3%)
9 135 1 28*24 35*31 25.0 5.50 (46%)
10 151 2 22*21 58*43 163.6 - 4.50 (- 21%)
11 111 1 45*36 61*52 35.6 4.00 (24%)
12 50 1 53*36 65*49 22.6 13.50 (75%)
13 137 1 34*30 48*45 41.2 3.00 (15%)
14 115 1 33*24 54*40 63.6 7.50 (26%)
15 108 1 46*34 61*50 32.6 6.50 (25%)
16 53 1 28*33 46*40 64.3 - 5 (- 9%)
17 164 2 92*60 112*68 21.7 - 1 (- 5%)
18 435 2 24*21 45*44 87.5 - 1 (- 7%)
19 118 1 52*41 64*46 23.1 4 (11%)
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for clinical management. Growth may cause doubt about
the initial diagnosis; but if imaging characteristics are
typical for FNH, this is not necessary. MRI with liver-
specific contrast agents in combination with CEUS has the
highest accuracy for FNH diagnosis [19–21]. Growth on
itself may not be an indication for biopsy: in our centre the
final recommendation on whether or not biopsy is deemed
necessary is made in a multidisciplinary liver tumour board
meeting. In general, our recommendation is to only per-
form a biopsy when a discrepancy in diagnosis exists
between the two imaging modalities.
It must be noted that the accuracy for diagnosing FNH
with MRI has improved significantly in the study period.
As of 2008, gadolinium-based contrast agents were used,
making distinction from hepatocellular adenoma more
accurate [22]. This could imply that some of the tumours
were inadequately diagnosed as FNH before 2008. How-
ever, by including only tumours that were diagnosed based
on two imaging modalities (MRI and CEUS), this pro-
portion was kept to a minimum. In the future, additional
analysis on the performed MRI with liver-specific contrast
could be performed. The method of choice of liver-specific
contrast is gadobenate dimeglumine. Another liver-specific
contrast agent that might be used is gadoxetic acid (Pri-
movist, Bayer Schering Pharma, Berlin, Germany). Quan-
titative analysis of the uptake of this liver-specific contrast
could help for the differentiation between HCA and FNH.
Grieser et al. showed the relative enhancement and liver-
to-liver enhancement of HCA were lower in HCA com-
pared to FNH with the use gadoxetic acid (Grieser
2013/2014) and might be the most recent method of choice
for FNH. Due to the inclusion period and the use of
Gadolinium chelate, additional analysis is not performed
and is one of the limitations of this study [23, 24].
Differences in management between FNH and hepato-
cellular adenomas demand an accurate differentiation.
Resection is indicated for hepatocellular adenoma if the
tumour exceeds a diameter of 5 cm 6 months after the use
of Oral Contraceptive is stopped, because of the risk of
Table 3 Summary of characteristics of growing FNH
Median follow-up time (months) 31 (IQR 25–42)
Location
Right hemiliver 10
Left hemiliver 9
Conservative treatment 18/19
Resection 4/19
Doubt about diagnosis due to growth 3
Symptomatic lesion 1
Fig. 3 Size-growing FNH. This figure shows T1 (a; diagnostic scan 2009) and T2 (b; follow-up scan 2012) of the FNH in which growth is
confirmed
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bleeding [25]. In contrast, for FNH, no strict indications for
resection are defined. As liver resections may have a peri-
operative complication rate up to 20–25%, a diagnostic
liver resection is not advisable [26]. In the case of FNH, the
liver resections are generally performed in young, healthy
women. As our study showed no complications of the
conservative approach, we advise to avoid resection as
described in the EASL clinical practice guideline [8], even
if the lesion is growing.
FNH is often an incidental finding discovered by various
imaging techniques. In our cohort, we found that 26.5% of
the patients were asymptomatic, while most studies have
shown a large percentage of asymptomatic patients ranging
from 65 [14] to 90% [27]. One possible explanation could
be that the Erasmus Medical Hospital is a tertiary referral
centre, and more patients with symptoms are referred. We
assume that most of the symptoms are not caused by the
presence of FNH and that FNH indeed could be asymp-
tomatic. If treated, patients need to be comprehensively
informed and it should be stressed that it may not be
guaranteed that the abdominal pain will resolve [28].
The biggest limitation of our retrospective study is the
design that is inherent to bias. In addition, it may be
questioned whether the sample size of the growing FNH
group is large enough to justify the conclusion; however,
with 19 patients, we are the first to describe such a series of
growing FNH and others may be challenged by this report
to add new data.
In conclusion, our series confirm that FNH is not a static
lesion and that growth may occur rather frequently. It must
be noted that patients with a growing FNH do not report
more pain or discomfort compared to the patients with non-
growing FNH. Moreover, growth in itself should not have
any implications on clinical management. In case of doubt,
MRI with liver-specific contrast agents in combination
with CEUS provides the highest diagnostic accuracy. As
these imaging techniques are not available in every hos-
pital, patients could be referred to a centre specialized in
focal liver lesions. Growth is not an indication for liver
biopsy, and biopsy should only be considered when the two
imaging modalities do not provide the same diagnosis.
This study shows that FNH may grow significantly
without causing symptoms. No adverse outcomes were
observed in patients with growing FNHs. Therefore, we
recommend, and use this in our hospital nowadays, that
even-growing FNHs should not be resected and follow-up
(growing) of FNH after a certain diagnosis made in a ter-
tiary referral centre is not indicated.
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